Myriad Genetics develops and commercializes molecular diagnostic tests that assess genetic risk and guide treatment decisions, best known for hereditary cancer testing including BRCA-related assays. Its portfolio spans oncology, women's health, and mental health pharmacogenetics, using gene-panel and biomarker technologies to inform screening and therapy choice. Customers include physicians, hospitals, and health systems that order lab-based genetic and companion diagnostic testing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 213.1 | — | -330.5 | — |
| Q3 2025 | 205.7 | — | -27.4 | — |
| Q4 2025 | 209.8 | — | -7.9 | — |
| Q1 2026 | 200.4 | — | -34.1 | — |
| Q2 2026 | 190.7 | -10.5% | -43.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ITHAX Acquisition Corp III (ITHA), Globa Terra Acquisition Corporation (GTERA), Alto Ingredients, Inc. (ALTO), The E.W. Scripps Company (SSP), Merlin, Inc. (MRLN), NI Holdings, Inc. (NODK)